Skip to main content
Top navigation
  • Sustainability reports
  • Focus area: Increase resource efficiency
  • Governance
  • Please fill out this field

Main navigation

    • Our offering
        • Solids & others
            • Manufacturing
                • Solids
                • Semi-solids
                • Liquids
                • Pharmaceutical packaging
                • Controlled drugs
                • High Potent
        • Sterile delivery
            • Manufacturing
                • Sterile vial filling
                • PFS and cartridges
                • Lyophilisation
                • Blow-fill-seal
                • Ampoules
            • Specialised services
                • Ophthalmics
                • Beta-lactams
                • Vaccine manufacturing
        • Advanced Bio
            • Modalities & services
                • xRNA therapies
                • Virus & viral vectors
                • Microbial & live biotherapeutic products
                • Recombinant proteins
            • Continuous manufacturing
            • Innovations & collaborations
        • Additional services
            • ReciPredict
            • Analytical services
            • Regulatory
            • Parenteral drug development
            • New product introduction
                • Technology Transfer
                • Product development
    • Resources
    • About us
        • About us
            • Our leadership
            • Why partner with us
            • Locations
        • Sustainability
            • Sustainability reports
            • Sustainability strategy
            • Net Zero commitment
            • Governance
        • News & Events
            • Press releases
            • Events
    • Careers
        • Careers
            • Who we are
            • Working with us
            • What you can do
            • Job search
    • Contact
Linkedin
Contact
Please fill out this field
No banner Image

  • Home
  • Facebook
  • Linkedin
  • Twitter
  • Email
April 16 2026
CEPI awards seed funding to Analysis Zero to advance real-time RNA vaccine quality testing using NMR technology
April 08 2026
Recipharm reports strong 2025 sustainability performance, advancing industry leadership
March 02 2026
Recipharm Advanced Bio to deliver series of seminar to U.S. FDA showcasing novel PAT and digital infrastructure to enable real-time testing and continuous biomanufacturing
February 19 2026
Recipharm strengthens high potency capabilities with new pilot and development investment
February 17 2026
Recipharm announces sale of Yavne, Israel facility and strategic commercial collaboration with Scinai
January 26 2026
Recipharm expands manufacturing to meet demanding FDA requirements
December 01 2025
Infant Bacterial Therapeutics AB secures partnership with Recipharm Advanced Bio for commercial production of drug substance
November 26 2025
Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support
October 28 2025
Recipharm secures major additional grant to develop AI-enabled manufacturing technologies
October 15 2025
Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Next page
  • Last page
Subscribe to

Footer Webfrom

contact form

Let’s discuss your 
next project

Share your details and start your journey with our global CDMO team.

Stay updated
https://se.linkedin.com/company/recipharm https://www.youtube.com/channel/UCr-bw7pCCkYZfeImOwTfNRg
Footer
  • Privacy policy
  • Cookies
  • Website terms
  • Sitemap
  • Cookie settings
  • Terms & conditions
  • Code of Conduct
© 2026

Recipharm AB. All rights reserved. RECIPHARM® is a registered trademark owned by Recipharm AB.

Delivered by Investisdigital [iDX]